An Arabinomannan-Protein Conjugate Vaccine for Tuberculosis

Arturo Casadevall of Albert Einstein College of Medicine in the U.S. will work to develop a new vaccine for tuberculosis that uses an arabinomannan-protein conjugate to elicit strong antibody-mediated immunity. M. tuberculosis has a polysaccharide capsule composed of arabinomannan, which, when used as part of a vaccine, could lead to an immune response that prevents inflammation and disease transmission without impairing clearance of the bacteria.